Imipenem/cilastatin: Pharmacokinetic profile in renal insufficiency

https://doi.org/10.1016/0002-9343(85)90102-0Get rights and content

Abstract

The pharmacokinetics of 250 mg each of intravenous imipenem and cilastatin in combination and 250 mg of cilastatin alone were studied in subjects with varying degrees of renal clearance. Renal disease did not change the volume of distribution of either drug. When the glomerular filtration rate was greater than 100 ml per minute, 48.6 percent of imipenem and 57.1 percent of cilastatin were recovered unchanged in the urine. Consequently, as the glomerular filtration rate declined, the half-life of imipenem increased from 1.02 hours in normal subjects to 3.69 hours in those undergoing dialysis. For cilastatin, the comparable values were 0.86 and 17.08 hours, respectively. The kinetics of cilastatin were unaffected by imipenem. The greater effect of renal disease on the half-life of cilastatin was due to a concomitant 87 percent reduction in nonrenal clearance. Both drugs were removed by hemodialysis. Dialysis reduced the half-life of imipenem from 4.80 to 2.45 hours and that of cilastatin from 16.63 to 3.86 hours. Therefore, dose adjustments will be required in patients with markedly reduced renal function and supplemental dosing will be required after hemodialysis.

References (17)

  • TP Gibson et al.

    Kinetics of procainamide and N-acetylprocainamide in renal failure

    Kidney Int

    (1977)
  • MW Anders

    Metabolism of drugs by the kidney

    Kidney Int.

    (1980)
  • GA Verpooten et al.

    The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure

    Br J Clin Pharmacol

    (1984)
  • SR Norrby et al.

    Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK 0787) in humans

    Antimicrob Agents Chemother

    (1983)
  • SR Norrby et al.

    Disposition of radiolabeled imipenem and cilastatin in normal human volunteers

    Antimicrob Agents Chemother

    (1984)
  • M Berman et al.
  • GP Stec et al.

    Kinetics of N-acetylprocainamide deacetylation

    Clin Pharmacol Ther

    (1980)
  • TP Gibson et al.

    Drug kinetics and artificial kidneys

    Clin Pharmacokinet

    (1972)
There are more references available in the full text version of this article.

Cited by (66)

  • Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review

    2021, Clinical Microbiology and Infection
    Citation Excerpt :

    The inclusion criteria were met for 25 studies; additionally, two studies were identified by manually screening the reference lists. Ultimately 27 studies were included [19–45]. The main reason for exclusion of studies was that the administered dose of antibiotics was not reduced in patients with impaired renal function (Fig. 1).

View all citing articles on Scopus

This work was supported by a grant from Merck Sharp and Dohme and the Research and Development Service of the Veterans Administration.

View full text